Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable.
The question about Reading a combination trial that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
Adding the measurement that the opening post says would settle it.
The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.
Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.
Not the whole picture, but the part of it I can speak to.
The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.
That matches what I was told, which is not the same as knowing it.
Agreed, and I will stop repeating the version of this I had been repeating.
Adding the boring version of Reading a combination trial, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Combination products complicate the certificate question considerably. Two active components mean two purity determinations and a ratio, and a single figure for a combination tells you almost nothing.
Adding the caveat now so it does not have to be extracted later.
The interest in combining it with semaglutide is that two different satiety mechanisms might add. Whether they do, and by how much, is exactly what the combination trials were designed to find out rather than something to be assumed.
I keep a log for Reading a combination trial specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.
Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.
This is the version I would want a new member to read first.
Marking my place. If it changes for me I will come back and say so.
Post #10 put the caveat in the right place and I want to underline it.
Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.
Injection-site tolerability is reported more often for this compound than for the incretins, and it is worth reading the trial reports rather than the summaries on that point specifically.
I am confident about the direction and much less about the magnitude.
Anyone reading a purity result for cagrilintide should know that its aggregation behaviour makes sample handling matter more than usual. A result on a sample that was warmed and cooled several times in transit is measuring the transit as much as the material.
The conclusion is tentative; the arithmetic underneath it is not.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
I would rather say I do not know than round it up to an answer.
Everything in post #14 holds. The case it does not cover is the one I have.
Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.
Confirming post #16 from a second method, which matters more than confirming it from a second person.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
It is the kind of thing that is obvious once and never again.
What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.
Where I would look next, rather than where I would stop.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.
Someone will know this better than I do and I hope they say so.
Answering the question post #19 raises rather than the one it answers.
Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.
What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
Everything in post #23 holds. The case it does not cover is the one I have.
I would keep Reading a combination trial and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
Narrowing post #27, because the general version has more than one answer.
The interest in combining it with semaglutide is that two different satiety mechanisms might add. Whether they do, and by how much, is exactly what the combination trials were designed to find out rather than something to be assumed.
Second-hand, so weight it accordingly.
Worth separating two things that post #27 runs together.
Reading a combination trial came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
This follows post #27 rather than contradicting it.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.